Robeco Institutional Asset Management B.V. 13F: Cuts DHR Stake by $73M
Key Points
- Robeco Institutional Asset Management B.V. lowered its holdings in Danaher Corporation by 330,568 shares, leaving a total of 84,148 shares valued at about $18.6 million.
- Danaher Corporation recently traded around $234.02, sitting above its 50-day and 200-day moving averages.
- Analysts hold a consensus strong buy rating on Danaher Corporation with a mean price target of $247.18.
Since the filing, $DHR is up 4.3% to date (from the $224.24 close on Oct 20, 2026).
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Robeco Institutional Asset Management B.V. reduced its holdings in Danaher Corporation by 330,568 shares, according to a Form 13F filed with the SEC on October 20, 2026. The filing shows the firm held 84,148 shares of the healthcare company at the end of the period, down from 414,716 shares previously. The remaining stake carried a reported value of $18,642,989. Danaher closed at $224.24 on the filing date.
DHR
Danaher Corporation
Robeco Institutional Asset Management B.V. vs. the S&P 500
Hypothetical returns from Robeco Institutional Asset Management B.V.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Robeco Institutional Asset Management's Danaher Corporation Position
The fund cut its position by 79.7% during the period. The sale left the firm with 84,148 shares, down from 414,716 shares in the prior quarter.
Other Institutional Activity in Danaher Corporation
Other large funds made adjustments to their Danaher holdings around the same time. Massachusetts Financial Services reduced its holdings by 167,287 shares, ending with 4,165,769 shares worth about $809.0 million. Montrusco Bolton Investments trimmed its stake by 152,432 shares to finish with 912,150 shares valued at approximately $202.1 million. DAVENPORT grew its holdings by 122,935 shares, ending with 801,278 shares worth about $178.4 million. Sustainable Growth Advisers cut its stake by 421,516 shares, holding 1,063,782 shares valued at roughly $235.7 million. Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3.6 billion.
Danaher Corporation Stock Up 4.4%
Danaher Corporation recently traded around $234.02 on October 22, 2026, up about 4.4% since the filing date. The stock trades above its 50-day moving average of $215.12 and its 200-day moving average of $201.26. Shares sit below the 52-week high of $242.80 and well above the 52-week low of $160.93.
Recent Earnings
Danaher generated $25.1 billion in trailing twelve month revenue and reported earnings of $6.04 per share. The company posted a net profit margin of 15.9% and a return on equity of 7.6%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share, which translates to a dividend yield of 0.71%. The company maintains a dividend payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Director Alan G. Spoon sold 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207. Chief Executive Officer Rainer M. Blair sold 58,255 shares on August 21, 2026, for a total value of $12.7 million.
Analysts Set New Price Targets
On October 5, 2026, RBC Capital maintained an outperform rating on the stock with a $250.00 price target, up from its previous target of $215.00. Barclays maintained an overweight rating with a $255.00 target on October 7, 2026, raising it from $230.00. Morgan Stanley maintained an overweight rating with a $240.00 target on October 13, 2026, increasing it from $220.00. TD Cowen maintained a buy rating with a $255.00 target on October 13, 2026, lifting it from $236.00. Later, on October 22, 2026, JP Morgan maintained an overweight rating and raised its target to $270.00 from $250.00. The stock carries a consensus strong buy rating with a mean price target of $247.18 across 22 analyst opinions.
About Danaher Corporation
Danaher Corporation designs and manufactures medical, research, and industrial tools and diagnostic systems. The company operates through biotechnology, life sciences, and diagnostics segments, supplying instruments used in laboratories and healthcare facilities around the world. Institutional adjustments like Robeco's latest filing offer a look at how major asset managers balance portfolios across the healthcare sector.
Bottom Line
Investors tracking Danaher will likely monitor upcoming earnings reports and further institutional filings for shifts in ownership. The stock continues to trade near the upper end of its 52-week range.
Related Filing Alerts
Source: Robeco Institutional Asset Management B.V.'s 13F filing on $DHR (Oct 20, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts